This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe


  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event, 7 - 9 June, 2022
Live In-Person Event: 7 - 9 June, Postillion Hotel AmsterdamDigital Experience: All Sessions Livestreamed 7 - 9 June

Jeremy Loyau, PhD
Senior Principal Scientist Display Technologies at Ichnos Sciences


Jeremy Loyau is Senior Principal Scientist at Ichnos responsible for the antibody discovery and optimization leading to the development of novel bi- or tri- specific immune engager therapeutics for cancer immunotherapy. He has led the implementation of Ichnos’ common light chain antibody discovery platform based on synthetic and immune phage display libraries and Next-Generation Sequencing of immune repertoires as a foundation of the BEAT 2.0 technology. He holds a PhD in biology from the University of Geneva and Novimmune where his research focused on antibody engineering using phage display and structural biology. He has published 2 first-author papers and is inventor on 4 patents application focusing on novel antibody therapeutics.

Agenda Sessions

  • Diverse and Highly Developable Common Light Chain Antibody Libraries to Enable the Next Generation of Multispecific Antibody Therapeutics